ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors

Published:2013-01 Issue:1 Volume:328 Page:144-151
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Huang Cheng-Po,Tsai Meng-Feng,Chang Tzu-Hua,Tang Wei-Chien,Chen Su-Yu,Lai Hsiao-Hsuan,Lin Ting-Yu,Yang James Chih-Hsin,Yang Pan-Chyr,Shih Jin-Yuan,Lin Shwu-Bin

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference47 articles.

1. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin. Proc.,2008

2. Epidemiology of lung cancer prognosis: quantity and quality of life;Yang;Methods Mol. Biol.,2009

3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;New Engl. J. Med.,2004

4. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

5. Gefitinib–a novel targeted approach to treating cancer;Herbst;Nat. Rev. Cancer,2004

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer stem cells: advances in knowledge and implications for cancer therapy;Signal Transduction and Targeted Therapy;2024-07-05

2. The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells;Biomedicine & Pharmacotherapy;2024-07

3. Identification of Novel Isatin Derivative Bearing a Nitrofuran Moiety as Potent Multi-Isoform Aldehyde Dehydrogenase Inhibitor;Molecules;2024-06-29

4. ALDH1A1 confers resistance to RAF/MEK inhibitors in melanoma cells by maintaining stemness phenotype and activating PI3K/AKT signaling;Biochemical Pharmacology;2024-06

5. Functional roles of microRNAs in vasculogenic mimicry and resistance to therapy in human cancers: an update;Expert Review of Clinical Immunology;2024-05-09